Cargando…

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma

Detalles Bibliográficos
Autores principales:	Sjöstrand, Maria, Sadelain, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316265/ https://www.ncbi.nlm.nih.gov/pubmed/36794501 http://dx.doi.org/10.3324/haematol.2022.282053

Ejemplares similares

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
por: Wong, Sandy W., et al.
Publicado: (2021)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
por: Battram, Anthony M., et al.
Publicado: (2022)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
por: Deng, Jingjing, et al.
Publicado: (2022)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
por: Zah, Eugenia, et al.
Publicado: (2020)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
por: Lin, Liang, et al.
Publicado: (2020)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
por: Wang, Ting, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma
por: Kennedy, Vanessa E., et al.
Publicado: (2021)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Li, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tdvqfq2vfo1gqm921r2j6f1ph0